Vorapaxar Meets End Point But Ups Bleeding Vorapaxar Meets End Point But Ups Bleeding
In its second phase 3 trial, Merck's novel antiplatelet agent reduced ischemic events but increased bleeding, including ICH. Results looked more promising in patients without a history of stroke. Heartwire (Source: Medscape Today Headlines)
Let Andrew Lansley's NHS medicine be put to the test
The Health Secretary has won the right to see his NHS reform Bill be given the chance to work, says Norman Tebbit. (Source: Telegraph Health)
